Neuropeptide S (NPS) is a recently discovered bioactive peptide that has shed new light on the neurobiology of sleep/wakefulness regulation and anxiety-like behavior. NPS can potently promote arousal and suppress all stages of sleep. This effect might be modulated by NPS receptors expressed in thalamic centers that are relays for transmitting arousing stimuli originating from the brainstem to the cortex. The peptide precursor is expressed most prominently in a novel nucleus located directly adjacent to the nora-drenergic locus coeruleus, a brain structure with well-defined functions in arousal, stress, and anxiety. NPS was also found to induce anxiolytic-like behavior in a battery of four different tests of innate responses to stress. This unique pharmacological profile of NPS offers significant potential for developing new drugs for the treatment of sleep and/or anxiety disorders.
Adolphs R, Gosselin F, Buchanan TW, Tranel D, Schyns P, Damasio AR. 2005. A mechanism for impaired fear recognition after amygdala damage. Nature433:68–72.
2.
Adolphs R, Tranel D, Damasio H, Damasio A.1994. Impaired recognition of emotion in facial expressions following bilateral damage to the human amygdala. Nature372:669–672.
3.
Aston-Jones G, Bloom FE. 1981. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci1:876–886.
4.
Aston-Jones G, Rajkowski J, Kubiak P, Valentino RJ, Shipley MT. 1996. Role of the locus coeruleus in emotional activation. Prog Brain Res107:379–402.
5.
Berridge CW, Foote SL. 1991. Effects of locus coeruleus activation on electroencephalographic activity in neocortex and hippocampus. J Neurosci11:3135–3145.
6.
Bourgin P, Huitron-Resendiz S, Spier AD, Fabre V, Morte B, Criado JR, and others. 2000. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci20:7760–7765.
7.
Bremner JD, Krystal JH, Southwick SM, Charney DS. 1996. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse23:28–38.
8.
Chaouloff F, Durand M, Mormede P.1997. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behav Brain Res85:27–35.
9.
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, and others. 1999. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell98:437–451.
10.
Cirelli C, Pompeiano M, Tononi G.1996. Neuronal gene expression in the waking state: a role for the locus coeruleus. Science274: 1211–1215.
11.
Civelli O, Nothacker HP, Saito Y, Wang Z, Lin S, Reinscheid RK. 2001. Discovery of novel neurotransmitters as natural ligands of orphan G protein-coupled receptors. Trends Neurosci24:230–237.
12.
Date Y, Ueta Y, Yamashita H, Yamaguchi H, Matsukura S, Kangawa K, and others. 1999. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A96:748–753.
13.
Drews J.2000. Drug discovery: a historical perspective. Science287:1960–1964.
14.
Foord SM. 2002. Receptor classification: post genome. Curr Opin Pharmacol2:561–566.
15.
Fukusumi S, Yoshida H, Fujii R, Maruyama M, Komatsu H, Habata Y, and others. 2003. A new peptidic ligand and its receptor regulating adrenal function in rats. J Biol Chem278:46387–46395.
16.
Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, and others. 1999. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A96:10911–10916.
17.
Hascoet M, Bourin M.1998. A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav60:645–653.
18.
He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, and others. 2004. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature429:188–193.
19.
Hunsley MS, Palmiter RD. 2003. Norepinephrine-deficient mice exhibit normal sleep-wake states but have shorter sleep latency after mild stress and low doses of amphetamine. Sleep26:521–526.
20.
Jiang Y, Luo L, Gustafson EL, Yadav D, Laverty M, Murgolo N, and others. 2003. Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155. J Biol Chem278:27652–27657.
21.
Jones BE. 2003. Arousal systems. Front Biosci8:438–451.
22.
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, and others. 1999. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell98:365–376.
23.
Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, and others. 1995. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature377:532–535.
24.
Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K.1999. Distribution of orexin neurons in the adult rat brain. Brain Res827:243–260.
25.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E.2000. Hypocretin (orexin) deficiency in human narcolepsy. Lancet355:39–40.
26.
Njunge K, Handley SL. 1991. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav38:63–67.
27.
Ohtaki T, Kumano S, Ishibashi Y, Ogi K, Matsui H, Harada M, and others. 1999. Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J Biol Chem274: 37041–37045.
28.
Paine TA, Jackman SL, Olmstead MC. 2002Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol13:511–523.
29.
Pare D, Quirk GJ, Ledoux JE. 2004. New vistas on amygdala networks in conditioned fear. J Neurophysiol92:1–9.
30.
Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. 1998. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci18:9996–10015.
31.
Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, and others. 1995. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science270:792–794.
32.
Rizvi TA, Ennis M, Aston-Jones G, Jiang M, Liu WL, Behbehani MM, Shipley MT. 1994. Preoptic projections to Barrington’s nucleus and the pericoerulear region: architecture and terminal organization. J Comp Neurol347:1–24.
33.
Sakurai T.2005. Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regul Pept126:3–10.
34.
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, and others. 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell92:573–585.
35.
Simon P, Panissaud C, Costentin J.1994. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine. Psychopharmacology114:597–600.
36.
Sved AF, Cano G, Passerin AM, Rabin BS. 2002. The locus coeruleus, Barrington’s nucleus, and neural circuits of stress. Physiol Behav77:737–742.
37.
Swanson LW, Hartman BK. 1975. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J Comp Neurol163:467–505.
38.
Swanson LW, Sawchenko PE, Rivier J, Vale WW. 1983. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology36:165–186.
39.
van der Werf YD, Witter MP, Groenewegen HJ. 2002. The intralaminar and midline nuclei of the thalamus. Anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Rev39:107–140.
40.
Wilson S, Bergsma DJ, Chambers JK, Muir AI, Fantom KG, Ellis C, and others. 1998. Orphan G-protein-coupled receptors: the next generation of drug targets?Br J Pharmacol125:1387–1392.
41.
Wise A, Jupe SC, Rees S.2004. The identification of ligands at orphan G-protein coupled receptors. Annu Rev Pharmacol Toxicol44:43–66.
42.
Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, and others. 2004. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron43:487–497.
